Metagenomi Therapeutics (MGX) Operating Income (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Operating Income of -$24.6 million for Q1 2026, up 11.62% year-over-year from -$22.0 million in Q1 2025, and down 0.9% quarter-over-quarter from -$24.4 million in Q4 2025.
Metagenomi Therapeutics (MGX) Operating Income (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Operating Income data on file, last reported at -$24.6 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$24.6 million, up 11.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$92.8 million (down 5.81% YoY), and the FY2025 annual result was -$96.0 million, down 8.0% from the prior year.
- Operating Income slipped to -$24.6 million in Q1 2026 per MGX's latest filing, from -$24.4 million in the prior quarter.
- Over five years, Operating Income peaked at -$16.9 million in Q2 2024 and troughed at -$29.0 million in Q1 2024.
- A 4-year average of -$22.2 million and a median of -$22.4 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2026: Operating Income tumbled 61.85% in 2024, then advanced 11.62% in 2026.
- A 4-year view of Operating Income shows it stood at -$20.2 million in 2023, then slipped by 2.11% to -$20.6 million in 2024, then fell by 18.15% to -$24.4 million in 2025, then fell by 0.9% to -$24.6 million in 2026.
- Business Quant data shows MGX's Operating Income at -$24.6 million in Q1 2026, -$24.4 million in Q4 2025, and -$22.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | Metagenomi Therapeutics | 46.60 Mn | 46.60 Mn | - | -24.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.59 Mn |
| Dec 31, 2025 | -24.37 Mn |
| Sep 30, 2025 | -22.84 Mn |
| Jun 30, 2025 | -20.99 Mn |
| Mar 31, 2025 | -27.82 Mn |
| Dec 31, 2024 | -20.62 Mn |
| Sep 30, 2024 | -22.38 Mn |
| Jun 30, 2024 | -16.86 Mn |
| Mar 31, 2024 | -29.03 Mn |
| Dec 31, 2023 | -20.20 Mn |
| Sep 30, 2023 | -22.40 Mn |
| Jun 30, 2023 | -17.96 Mn |
| Mar 31, 2023 | -17.94 Mn |